Kornam, tablets 2 mg 30 pcs

Cornam is a blocker of peripheral postsynaptic a₁ adrenoreceptors. It causes dilation of arterioles and venules, decreases OPPS and venous return to the heart, as a result BP decreases. After a single dose of the drug, the hypotensive effect lasts for 24 hours.

Blocking a₁ adrenoreceptors of smooth muscles of the prostate and bladder neck, the drug promotes normalization of urination in patients with benign prostatic hyperplasia.

The preparation promotes normalization of lipid metabolism: decreases quantity of cholesterol, triglycerides and low and very low density lipoproteins in blood while increasing quantity of high density lipoproteins.
With systematic use of Kornam regression of left ventricular hypertrophy is noted.

Indications

Active ingredient

Composition

1 tablet contains:

therazosin (in the form of dihydrate hydrochloride) 2 mg.

How to take, the dosage

In benign prostatic hyperplasia, the initial dose is 1 mg once daily before bedtime. Gradually the dose is increased to 2-10 mg/day until the optimal effect is achieved. Therapeutic effect is usually observed 2 weeks after the start of treatment. To achieve a persistent effect the course of treatment should be 4-6 weeks.

In arterial hypertension, the drug is prescribed in an initial dose of 1 mg/day before bedtime. The dose is gradually increased until clinical effect is achieved. The maintenance dose is 1-10 mg once daily. The maximum daily dose is 20 mg. In case of temporary discontinuation of the drug, treatment is resumed according to the same scheme.

Interaction

In concomitant use of Kornam and beta-adrenoblockers, diuretics, calcium channel blockers, ACE inhibitors may increase the antihypertensive effect. Special caution is required when concomitant administration of terazosin and antihypertensive drugs of central action.

The absorption of terazosin is reduced with concomitant administration of adsorbents and antacids.

Adrenomimetics weaken the effect of terazosin.

Concomitant use of terazosin and NSAIDs may decrease antihypertensive effect due to inhibition of prostaglandin synthesis and retention of fluid and sodium ions.

Special Instructions

To prevent the development of orthostatic arterial hypotension, treatment should begin with administration of Kornam at a dose of 1 mg/day before bedtime, after which the patient should be in bed for 6-8 hours.

The risk of orthostatic arterial hypotension (“first-dose effect”) is highest within 30-90 minutes after drug administration and increased in patients receiving beta-adrenoblockers and diuretics simultaneously, with decreased RBC, hyposolic diet, and when resuming treatment with the drug after a break (several days).

In case of temporary discontinuation of treatment, therapy is resumed with the same dose. In the course of treatment the level of specific antigen of the prostate gland does not change. Before initiating therapy of benign prostatic hyperplasia, prostate cancer must be excluded.

The patient must be informed about the increased risk of orthostatic hypotension with alcohol consumption, prolonged standing or exercise, and hot weather.

Within 12 hours after the first dose, after increasing the dose, or after discontinuing therapy, it is not recommended to engage in potentially hazardous activities that require increased attention and quick psychomotor reactions.

Contraindications

With caution, prescribe the drug in angina, CHD, hepatic or renal failure, impaired cerebral circulation, type 1 diabetes.

Side effects

Cardiovascular system: rare – orthostatic hypotension.
CNS: drowsiness, dizziness, asthenia.
Others: nasal congestion.

Cardiovascular system side: orthostatic hypotension – “first-dose effect” (observed in 1% of patients, mostly receiving concomitant diuretics or beta-adrenoblockers), manifested by dizziness, tachycardia, fainting may occur; rarely – palpitations, peripheral edema, nasal congestion.
CNS: rarely – dizziness, asthenia, somnolence, visual perception failure.
Blood system: decrease (associated with hemodilution) of hematocrit, hemoglobin, leukopenia, hypoproteinemia, hypoalbuminemia.
Other: rare – decreased potency, nausea.

Overdose

Symptoms: pronounced decrease in BP, impaired coordination of movements, fainting.

Treatment: it is necessary to lay the patient with the head end of the bed down. If necessary, prescribe hypertensive agents, IV fluid administration. Hemodialysis is not effective.

Pregnancy use

Cornam can be used in pregnancy and during breastfeeding if the potential benefit to the mother outweighs the possible risk to the fetus or infant.

Similarities